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Prior evidence suggests that early, improved control of glycemic control likely lowers the risk of 
some combination of microvascular and/or macrovascular complications. Furthermore, growing 
evidence suggests that not only achieving a certain degree of control, but how that control varies 
also may matter in terms of outcomes. Finally, there is some initial evidence that clinical 
pharmacy specialist (CPS) services can, on average, lower glycosylated hemoglobin (HbA1c) 
and improve glycemic control. However, there is insufficient evidence characterizing variation in 
glycemic control outcomes in patients receiving CPS management of diabetes and factors 
associated with greater chance of success with that management. 
Methods: 
This is an observational, multicenter, retrospective cohort study of Veterans with type-2 diabetes 
in Veterans Integrated Service Network 15 managed by clinical pharmacy specialists between 
7/1/2013 and 7/1/2017 with a baseline HbA1c level ≥ 8%. Glycosylated hemoglobin 
measurements were collected for two years following the index date and used to group patients 
into distinct patterns of HbA1c trajectories over time using group-based trajectory modeling and 
posterior probabilities of group membership. Characteristics associated with successful HbA1c 
trajectories and association of assigned trajectories with all-cause and diabetes-related 






A total of 4,119 Veterans were included and successfully divided into six distinct HbA1c 
trajectory groups: High Gradually Decreasing (n=325, 7.9%), Moderate Early Decline (n=1692, 
41.1%), Large Early Decline (n=231, 5.6%), Uncontrolled Stable (n=1468, 35.6%), Early 
Decline / Subsequent Increase (n=266, 6.5%), and Very Uncontrolled Stable (n=137, 3.3%). The 
Large Early Decline, Moderate Early Decline, and High gradually decreasing groups were 
classified as successful. Successful trajectories were more likely to reach a target HbA1c of ≤ 
7%, have shorter duration of pharmacist management, greater utilization of nutrition clinic 
services. The distinguishing factor between successful and less successful trajectories appears to 
be the progress made within the first six months of pharmacist management.  
Conclusion: 
Patients managed for diabetes can be grouped into distinct patterns of change in glycemic control 
over time. The first six months of the clinical pharmacist/patient relationship may be important 
in determining a patient’s overall success. Future research is needed to identify pharmacist 
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Diabetes is a chronic illness that continues to be a serious public health problem, particularly in 
the Department of Veterans Affairs (VA), with an estimated prevalence among Veterans of 
20.5% in 2013-2014 as compared to 15.5% in 2005-2006.1 Also, according to 2010-2014 
NHANES data, approximately 49% of patients nationally with diabetes are not meeting the 
generally recommended target for glycemic control of a hemoglobin A1c < 7%.2 Controlling 
glycemic status in diabetes is an important measure of quality of primary care services. Keeping 
HbA1c at least < 9% is a mainstay in the Healthcare Effectiveness Data and Information Set 
(HEDIS) measures.3 HEDIS is a set of outpatient care performance metrics utilized by many 
health plans including Medicare. The VA system has adopted a quality measurement system for 
its medical centers called Strategic Analytics for Improvement and Learning (SAIL) to rate the 
quality of VA medical centers.4 HEDIS measures make up an important component of the SAIL 
framework as well as including limiting admissions related to ambulatory care sensitive 
conditions, which are conditions that, if managed well as an outpatient, for instance diabetes, 
should not result in hospital admission.  
 
Numerous studies have documented the benefits of glycemic control in diabetes. In 1993, the 
Diabetes Control and Complications Trial (DCCT) showed intensive glycemic control (achieved 
HbA1c of approximately 7% versus about 9%) in type-1 diabetes delayed the onset and 
progression of microvascular diabetes complications of retinopathy, nephropathy, and 
neuropathy.5 Interestingly, the Epidemiology of Diabetes Interventions and Complications study 
(EDIC) extended  follow-up of patients in the DCCT cohort for up to 8-14 additional years and 
found sustained benefit in delayed development of microalbuminuria and reduced rates of 




pattern of diabetes control (e.g. early intensive control) may also matter rather than simply 
overall average achieved level of glycemic control. Similar results were seen in 1998 with the 
United Kingdom Prospective Diabetes Study (UKPDS) in terms of reduced risk of microvascular 
complications with intensive glycemic control (HgbA1c 7% on average) versus less intensive 
control (approximately 8% on average) over 10 years in type-2 diabetes.8,9  
 
Conversely, subsequent to these early trials, major RCTs showed some more nuanced results. 
Specifically, the ADVANCE trial showed modest improvement primarily in the rate of 
nephropathy at the cost of increased rates of severe hypoglycemia.10 However, the ACCORD 
and VA Diabetes Trial (VADT) studies failed to show meaningful improvements in 
macrovascular or microvascular outcomes with “intensive” versus “standard” therapy.11,12 
However, there are major differences between the DCCT/EDIC/UKPDS studies as compared to 
ADVANCE/ACCORD/VADT. Specifically, in the more recent ADVANCE/ACCORD/VADT 
studies, the study population was older and have had diabetes for a longer period of time prior to 
study enrollment. However, most importantly, in these subsequent analyses those in the 
“standard therapy” arms in these more recent trials achieved lower HbA1c of approximately 7-
8% rather than 7.9-9% in DCCT and UKPDS.8-12 Additionally, higher rates of severe 
hypoglycemia were observed in the intensive therapy groups of ACCORD/ADVANCE with 
achieved average HbA1c in those groups of approximately 6.5%.10-11 
 
Consequently, the 2019 American Diabetes Association Standards of Medical Care in Diabetes 




goal to < 8% for those patients in more challenging situations such as with a history of severe 
hypoglycemia or advanced diabetes complications.13 
 
While general HbA1c targets are now well established, instead of viewing diabetes control as a 
single measurement at one time point a logical question to ask would be, does the pattern of 
glycemic control/HbA1c over time matter? An emerging area of research is developing through 
utilization of group-based trajectory modeling which is an approach used to visualize distinct 
groupings of patterns of how an outcome (e.g. HbA1c) changes over time and effects of those 
patterns on outcomes.14-18 A retrospective analysis was completed utilizing the Kaiser 
Permanente Northern California Diabetes Registry to analyze the association of ten-year HbA1c 
trajectories on diabetes complications and mortality.16 The authors fit the data with five distinct 
trajectory groups of HbA1c control. All HbA1c trajectory groups were associated with higher 
hazard of microvascular complications as compared to the “low stable” trajectory group which 
had a relatively stable trajectory of A1c between 7-7.5%. Also, the ‘High decreasing early’ 
trajectory showed an increased mortality risk as compared to the ‘low-stable’ group after 
controlling for mean 10-year achieved HbA1c. An earlier study in a Veteran population modeled 
trajectories of HbA1c through modeling with use of a time-varying covariate for HbA1c and 
found that baseline HbA1c level was associated with greater risk of mortality and suggested that 
the slope of the trajectory HbA1c may also be associated with difference in mortality.17 Another 
analysis suggested that those with a ‘moderate-increasing’ trajectory of HbA1c is associated with 
more progression of chronic kidney disease as compared to those classified as ‘near-optimal 
stable’.18 Another recent study conducted in Singapore, classified patients with type 2 diabetes 




‘moderate-increase’ and ‘high-decrease’ subgroups) had an increased rate of stroke, end stage 
renal disease, and death as compared to the ‘low-stable’ trajectory.19 Finally, while attaining 
glycemic control is typically sought to prevent traditional microvascular and macrovascular 
complications of diabetes, another study investigated trajectories of HbA1c control over time 
with cognitive outcomes in the elderly, providing some evidence to suggest that non-stable 
trajectories of HbA1c may be associated with adverse impacts on cognitive performance.20 
 
Clinical pharmacy specialists (CPS) are becoming increasingly utilized as part of primary care 
teams to provide chronic disease management services. VA CPSs are credentialed prescribers as 
members of the medical staff. They are required to have appropriate baseline credentials and 
experience to justify their advanced scope of practice. This often occurs through specialized 
post-graduate training, for example in ambulatory care. A published systematic review by VA 
Health Services Research and Development summarized current evidence on the outcomes of 
CPS services, including those related to management of diabetes.21 The authors noted a common 
outcome in these studies was “Goal Attainment”, meaning the effectiveness at achieving 
guideline recommended targets for control of chronic illnesses (e.g. diabetes/hypertension, etc.). 
In combined results of 6 randomized clinical trials (RCT), pharmacist-led care improved goal-
attainment for diabetes compared to usual care (RR: 1.83, 95% CI: 1.44 – 2.33). However, 
studies examining the benefits of CPSs on other outcomes were of lower quality.  
 
Recently, some analyses have shown clinical benefit to CPS management of diabetes in the VA. 
One analysis was conducted at the Memphis VA by retrospective review of 62 CPS managed 




solely by primary care providers (PCP) between 2012 and 2014.22 They were able to show a 
significant reduction in HbA1c in the CPS group of approximately 1.5 percentage points from 
baseline over the course of approximately 14 months as compared to solely PCP management.  
Another study was conducted at the Cincinnati VA that showed a significant reduction in HbA1c 
of an average of 2.2% from baseline over an average of 18 months with CPS diabetes 
management.23 Though this was a pre/post analysis and did not include a standard of care 
comparator group. Additionally, another retrospective analysis was conducted in a non-VA 
internal medicine setting where 82 patients were evaluated against themselves as their own 
controls comparing a “usual care” run-in phase, to a subsequent pharmacotherapy clinic 
management phase showing an average reduction of 1.6% in HbA1c in the intervention phase 
compared to usual care.24 Finally, a study by Maeng et al demonstrated a reduction in all-cause 
hospitalization rate (-19.2%, p = 0.02), lower medical costs (-13%, p=0.027), more primary care 
provider visits (18.5%, p < 0.001), and a greater proportion of patients attaining goal HbA1c 
(57% vs. 51%, p < 0.0001) compared to a cohort not enrolled in pharmacist diabetes 
management.25 Finally, a recent nationwide retrospective cohort study of the effectiveness of VA 
CPSs in managing uncontrolled diabetes in 53 VA medical centers with over 12,000 patients and 
propensity-score matched controls showed that  CPS providers managed diabetes as well as 
primary care providers.26  
 
While clinical pharmacist management of diabetes can likely assist with goal attainment, due to a 
limited number of available trained pharmacy specialists, from a practical perspective it is 
difficult to ascertain which patients are likely to benefit from pharmacist management versus not. 




are a limited number of clinical pharmacy specialist providers as compared to the total 
population of patients with diabetes. There is currently limited evidence investigating this 
question on factors associated with successful results from pharmacist management of diabetes. 
Lam et al. attempted to address this question by dividing a cohort of pharmacist managed 
patients into those classified either as clinical success (HbA1c reduction ≥ 2% or final HbA1c < 
8%) or alternatively clinical failure.27 They classified 44.7% of their population as clinical 
successes, showing variability in effectiveness. They attempted to identify factors associated 
with either success or failure. They identified history of cerebrovascular accident (CVA) and 
higher baseline HbA1c as predictors of success and use of short-acting insulin or a greater 
number of classes of diabetes medications used as predictors of failure. These results are 
challenging to interpret, there is no plausible rationale why a history of CVA would be more 
likely to have success with pharmacy management, thus this may be related to a confounding 
factor, such as increased healthcare utilization. Conversely, these results would indicate lack of 
success with more challenging diabetes patients prescribed multiple classes of medications, 
however, with a lack of a comparator group not utilizing pharmacy services, this could be 
measuring a “more difficult to manage” patient that other types of providers may also have less 
overall success with managing.    
 
Overall, in general, improved glycemic control likely helps prevent microvascular and 
macrovascular complications, though there is a growing body of evidence suggesting that 
additional factors such as how glycemic control changes over time may play an important role. 
There is also some initial, encouraging evidence that clinical pharmacy specialists can play a role 




characterizing how clinical measures change over time with CPS management of diabetes and 
factors associated with a greater chance of successful improvement in HbA1c with pharmacist 














2.1 Study Design 
This is a retrospective, multi-site, cohort study of Veterans with type 2 diabetes mellitus (T2DM) 
who have received disease management services for T2DM within Veterans Integrated Service 
Network (VISN) 15 which consists of eight VA medical centers across three midwestern states 
including Kansas, Missouri, and Illinois. This study was approved by the Kansas City VA 
Institutional Review Board and the VA Eastern Kansas Healthcare System Research and 
Development Committee.  
 
The study population was identified using the national Corporate Data Warehouse (CDW) 
database (VA 79 FR 4377) using resources and facilities at the VA Informatics and Computing 
Infrastructure (VINCI), (VA HSR RES 13-457).28  
 
2.2 Cohort Derivation 
Patients were identified by use of a flag set through use of an electronic health factor set in the 
medical record indicating that the patient had seen a pharmacist for management of T2DM 
between July 1, 2013 and July 1, 2017. The date of the patient’s first appointment with a 
pharmacist for management of diabetes during this interval was considered the index date.  
 
Patients were excluded if their baseline glycosylated hemoglobin (HbA1c) nearest to the index 
date (between six months prior and one month after) was < 8% or if a baseline HbA1c could not 




the one-year prior to the index date, or if they did not have at least two subsequent visits with a 
pharmacist for diabetes management following the index date. Veterans with a baseline HbA1c < 
8% were excluded as some Veterans may be given slightly higher HbA1c goals due to co-
morbidities and extent of diabetes related complications as consistent with current guideline 
recommendations.13  
 
2.3 Outcomes and Data Collection 
The primary outcome was change in HbA1c over two-years in a cohort of patients managed by 
clinical pharmacy specialists for T2DM through classifying patient HbA1c trends into distinct 
trajectories. Secondary outcomes were to evaluate factors associated with a successful trajectory 
of change in HgbA1c versus unsuccessful, with success defined as a sustained decrease in 
HbA1c over the follow-up period. The proportion of patients achieving a goal HbA1c of ≤ 7% at 
some point during the second of the two-year follow-up period was determined. Finally, as an 
exploratory, hypothesis-generating analysis, occurrence of all-cause and diabetes-related 
hospitalization and association with glycemic control trajectory groups was determined. Patients 
were followed retrospectively for the entire two-year period, even if clinical pharmacy specialist 
management of diabetes had ceased.  
 
Data were collected from the electronic health record utilizing Microsoft SQL Server query. 
Demographic and clinical data collected at baseline included sex, age, race, weight (within 6 
months prior or 3 months after the index date), blood pressure (within 90 days of the index date), 




1-year prior or 90 days after the index date (serum creatinine, low density lipoprotein, high 
density lipoprotein, triglycerides, and total cholesterol), and hypoglycemic medications (within 6 
months prior to the index date). Additional data collected during the two-year post-index study 
period included HbA1c at 3-month intervals, hypoglycemic medication dispensed within the year 
following the last pharmacist visit, blood pressure and lipid profile as of the last pharmacist visit, 
diagnosis of alcohol or substance use disorders, nutrition or weight management visits, 
participation in the home telehealth program, number of pharmacy visits for diabetes 
management, and the proportion of those visits that were conducted via telephone or via clinical 
video telehealth technology.  
 
Diagnoses for co-morbidities were determined from ICD9/ICD10 coding from electronic 
medical record problem lists, inpatient admissions, and outpatient visits. For each 3-month 
interval, the closest HbA1c reading to the appropriate time interval from the index date (e.g. 3 
months, 6 months, 9 months, etc.) was taken between two months prior and 1 month following 
that date ensuring the same HbA1c reading is not used for more than one interval.   
 
2.4 Statistical Analysis 
All analyses were performed using SAS Enterprise Guide Version X (SAS, Cary, NC, USA) 
within the VINCI environment. The VINCI environment is a secure research environment hosted 
on centralized VA servers. Group-based trajectory modeling using PROC TRAJ in SAS was 
utilized using a censored normal model to group patients into defined and distinct trajectories of 




trajectory groups to include in the model was determined based on selecting the number of 
groups that minimized the Bayesian Information Criterion (BIC) up to a maximum total number 
of groups with each group initially modeled as a quadratic-order equation or one zero-order 
equation and the rest quadratic order if it is thought that one group may have a trajectory that 
does not change with time.31 A maximum of six groups was chosen as a larger number of groups 
would be difficult to clinically interpret. Subsequently, each group was tested in order by 
adjusting the shape (or order of the polynomial) of each trajectory group to minimize the total 
model BIC. Terms were added to the model for each group until the BIC began to increase. Two 
times the change in BIC between the prior model and the more complicated model was also used 
to evaluate the benefit of including more terms in the model where larger negative values 
indicated greater support for keeping the more complicated model.32 After trajectories were 
determined, patients were assigned to a single trajectory group by SAS based on posterior 
probabilities of group membership from the output of the PROC TRAJ procedure.31 Trajectory 
groups were then categorized as either “successful” or “unsuccessful” based on visual inspection 
with “successful” groups illustrating a sustained reduction in HbA1c. Subsequently, logistic 
regression was utilized to evaluate for characteristics associated with successful versus 
unsuccessful trajectory groups. Variables included in the final regression model were determined 
through backwards elimination with a p-value to stay in the model of 0.1. The final model was 
evaluated with the Hosmer and Lemeshow Goodness-of-fit test and by comparing the results of 
the reduced model with the full model including all predictors.  
 
Logistic regression was also utilized to evaluate the association of glycemic control trajectories 




was determined based on a list of treating specialties published by Vincent et al.33 Model 
selection and evaluation was performed as stated above; however, the assigned glycemic control 
trajectory group was included in the model regardless of significance as this was the primary 
predictor of interest. 
  
Baseline and study period characteristics across trajectory groups were analyzed by Pearson 2 
test for categorical variables and ANOVA for continuous variables. For continuous data, 
normality of the data was assessed through inspection of the QQ plot and equality of variances 
was assessed through inspection of a plot of predicted versus residual values for any obvious 
patterns. If the data showed obvious deviations from normality, the Kruskal-Wallis test was used. 
Characteristics by success or not were analyzed by Pearson 2 test for categorical variables and 
student t-test for continuous variables. For continuous measures, if normality could not be 
assumed, the Wilcoxon Rank Sum test was used. Equality of variances was assessed using the 
folded F statistic. If variances could not be assumed to equal, the Satterthwaite method was used 
instead of pooled variance. The 2-sided alpha level was set at 0.05 hence, p-values < 0.05 was 















3.1 Cohort Development 
 
A total of 10,331 Veterans met the study inclusion criteria which comprised the initial cohort. 
After excluding patients with no appropriate HbA1c measurement at baseline (n = 231), a 
baseline HbA1c < 8% (n = 3,375), less than three total pharmacy visits for management of 
T2DM (n = 2,710), or a pharmacy visit for management of T2DM within the year prior to the 
index date (n = 1,233) a final cohort of 4,119 Veterans was established (Figure 1). 
 





3.2 Trajectory Model Development 
Model selection to determine the optimal fit of trajectory groups to the data was conducted as 
previously stated through first determining the optimal number of groups up to the maximum of 
six groups and then determining the best equation order to model each group by minimization of 
BIC. It was decided to begin with a two-group model including a zero-order group and a 
quadratic order group, as it was conceivable that there was a group with an essentially unchanged 
HbA1c throughout the study period.31 Further details regarding the steps of determining the final 
model can be located in Appendix A.  
 
In the final model, patients fell into six distinct trajectory groups of HbA1c over time (Figure 2): 
High gradually decreasing, moderate early decline, large early decline, uncontrolled stable, early 
decline/subsequent increase, and very uncontrolled stable. 
 
 









1 = High Gradually Decreasing (n=325, 7.9%), 2 = Moderate Early Decline (n=1692, 41.1%) 
3 = Large Early Decline (n=231, 5.6%), 4 = Uncontrolled Stable (n=1468, 35.6%) 
5 = Early Decline/Subsequent Increase (n=266, 6.5%), 6 = Very Uncontrolled Stable (n=137, 3.3%) 
 
Figure 3: Trajectory group changes in HbA1c over time 
 
In order to determine model adequacy, several analyses were conducted to check the model. 
Firstly, the average of the posterior group probabilities of subjects assigned to each group were 
determined for each group. Ideally, the average posterior probability for the assigned group 
would be 1, however, average posterior probabilities above 0.7 indicate acceptable fit to the 
model.31 All group average posterior probabilities for this model were above 0.8 (Appendix B). 




indicating acceptable fit of the data to the model (Appendix B).31 Finally, the estimated group 
probabilities in the population should be similar to the proportion of subjects assigned to each 
group, leading to a ratio at or near 1, which was also observed for this sample (Appendix B).31 
Overall, these data seem to fit reasonably well to these six modeled trajectory groups.   
 
As illustrated from Figure 1, despite patients being classified into six distinct trajectory groups of 
HbA1c over time, a large majority of patients fell into either the ‘Moderate Early Decline’ or the 

























3.3 Trajectory Group Characteristics 
 
Baseline and study period characteristics of patients assigned to each glycemic control trajectory 
group can be seen below in Table 1. 
Table 1: Characteristics based on assigned trajectory group 
 
High Gradually 






Decline          
(n = 231)
Uncontrolled 
Stable               
(n = 1468)
Early Decline / 
Subsequent 




Stable              
(n = 137)
Age, yrs (SD)* 60.5 (10.3) 65.3 (9.4) 62.5 (10.5) 65.1 (9.8) 60.4 (10.5) 57.2 (10.1)
Male, no. (%) 312 (96) 1641 (97) 226 (97.8) 1421 (96.8) 251 (94.4) 130 (94.9)
Race, no. (%)*
White 216 (66.5) 1323 (78.2) 150 (64.9) 1151 (78.4) 192 (72.2) 76 (55.5)
Black or African American 90 (27.7) 296 (17.5) 66 (28.6) 237 (16.1) 61 (22.9) 53 (38.7)
Other 19 (5.8) 73 (4.3) 15 (6.5) 80 (5.5) 13 (4.9) 8 (5.8)
BMI, kg/m2 (SD)◊ 33.9 (7.2) 34.1 (6.6) 32.4 (6.0) 34.2 (6.7) 33.9 (6.5) 32.9 (6.6)
Pharmacy Visits, no. (SD)◊ 10.6 (8.7) 10.1 (7.2) 10.2 (8.4) 12.1 (8.7) 9.5 (7.7) 7.3 (5.2)
Telephone Visit, %, (SD) 9.8 (23) 13.4 (26.9) 12.6 (25.4) 13.3 (26.2) 9.4 (22) 12.7 (23.1)
Clinical Video Telehealth, % (SD) 1.6 (9.9) 0.97 (8.5) 1.6 (10.1) 1.5 (10.8) 0.8 (8.1) 1.5 (10)
Home Telehealth, %* 85 (26.2) 314 (18.6) 41 (17.8) 376 (25.6) 71 (26.7) 30 (21.9)
Nutrition/Weight Mgmt, %*
0-1 Visits 237 (72.9) 1322 (78.1) 162 (70.1) 1123 (76.5) 200 (75.2) 99 (72.3)
2-5 Visits 57 (17.5) 239 (14.1) 49 (21.2) 229 (15.6) 50 (18.8) 32 (23.4)
6+ Visits 31 (9.5) 131 (7.7) 20 (8.7) 116 (7.9) 16 (6) 6 (4.4)
Pharmacy follow-up duration (SD)*
< 6 Months 57 (17.5) 493 (29.1) 86 (37.2) 239 (16.3) 61 (22.9) 42 (30.7)
6-12 Months 84 (25.9) 442 (26.1) 53 (22.9) 372 (25.3) 95 (35.7) 50 (36.5)
≥ 12 Months 184 (56.6) 757 (44.7) 92 (39.8) 857 (58.4) 110 (41.4) 45 (32.9)
Baseline A1c, % (SD)◊ 11.7 (1.4) 9.2 (1.0) 13.5 (1.4) 9.5 (1) 10.3 (1.4) 12.5 (1.7)
Creatinine Clearance, %*
≥ 60 ml/min 279 (85.9) 1398 (82.6) 192 (83.1) 1168 (79.6) 229 (86.1) 120 (87.6)
30-59 ml/min 35 (10.8) 191 (11.3) 33 (14.3) 185 (12.6) 21 (7.9) 8 (5.8)
< 30 ml/min 0 23 (1.4) 2 (0.9) 24 (1.6) 0 1 (0.7)
Unknown 11 (3.4) 80 (4.7) 4 (1.7) 91 (6.2) 16 (6) 8 (5.8)
BP, baseline, mmHg (SD)◊ 136/79 (18/12) 133/76 (17/12) 131/78 (16/12) 135/76 (18/12) 134/79 (17/13) 133/79 (16/12)
BP, final, mmHg (SD) [DBP*] 134/77 (19/12) 133/75 (18/11) 132/77 (18/11) 133/75 (18/12) 134/78 (21/14) 134/81 (22/14)
Lipid levels, mg/dl, baseline:
Total Cholesterol (SD)◊ 195.8 (69.5) 168.1 (51.2) 188 (57.1) 168 (70.5) 178.4 (53.7) 194.5 (53.4)
Triglycerides (SD)◊ 298.1 (407.3) 227.2 (230.2) 276.3 (234.9) 214.8 (188) 231.9 (201.4) 236.6 (184.3)
HDL (SD)◊ 38.1 (9.7) 36.7 (9.8) 36.4 (8.7) 36.7 (9.9) 37.6 (10.2) 39.7 (10.3)
LDL (SD)◊ 106.3 (43.2) 91 (34.6) 105.5 (45.5) 91.1 (33.7) 98.7 (38) 111.7 (41.6)
Lipid levels, mg/dl, final visit
Total Cholesterol (SD)◊ 170.6 (48.1) 150.8 (42.3) 158 (48.6) 155.8 (43.2) 170.7 (47.4) 193.4 (55.9)
Triglycerides (SD)◊ 207.3 (162.7) 173.6 (121.8) 186.9 (188.8) 188.3 (161.7) 219.6 (188.6) 254.6 (239.9)
HDL (SD)◊ 37.5 (9.8) 36.6 (9.2) 36.8 (9.4) 36.4 (9.3) 37.3 (9.9) 39.3 (10)
LDL (SD)◊ 96.6 (39.6) 82.1 (31.3) 87.6 (33.6) 85.2 (32.7) 94.5 (35.6) 108.4 (43.9)






Across trajectory groups, patients were relatively similar. Patients were mostly male with 
average ages of approximately 60 years with BMI > 30 kg/m2, sufficient renal function, and 
relatively well controlled blood pressure. As would be expected, HbA1c at baseline was 
significantly different among glycemic control trajectory groups, with as expected, a majority of 
patients falling into trajectory groups starting from a modestly uncontrolled HbA1c on average 
High Gradually 






Decline          
(n = 231)
Uncontrolled 
Stable               
(n = 1468)
Early Decline / 
Subsequent 




Stable              
(n = 137)
Medications, Baseline
Total, no. (SD)◊ 2.03 (0.96) 1.94 (0.99) 1.81 (1.11) 2.14 (0.96) 2.08 (0.97) 1.93 (1.07)
Metformin, % 162 (49.9) 958 (56.6) 121 (52.4) 787 (53.6) 151 (56.8) 65 (47.5)
Sulfonylurea, %* 104 (32) 652 (38.5) 67 (29) 552 (37.6) 90 (33.8) 39 (28.5)
DPP-4 Inhibitor, %* 18 (5.5) 151 (8.9) 13 (5.6) 119 (8.1) 16 (6) 3 (2.2)
GLP-1 Agonist, % 1 (0.3) 16 (1) 2 (0.9) 25 (1.7) 3 (1.1) 2 (1.5)
SGLT-2 Inhibitor, % 0 1 (0.1) 0 2 (0.1) 0 0
Thiazolidinedione, % 12 (3.7) 50 (3) 8 (3.5) 41 (2.8) 9 (3.4) 2 (1.5)
Insulin, %*
Basal/Bolus 137 (42.2) 562 (33.2) 74 (32) 635 (43.3) 113 (42.5) 57 (41.6)
Basal Only 78 (24) 316 (18.7) 55 (23.8) 305 (20.8) 50 (18.8) 35 (25.6)
Prandial Only 8 (2.5) 18 (1.1) 5 (2.2) 36 (2.5) 8 (3) 3 (2.2)
U-500 2 (0.6) 2 (0.1) 0 4 (0.3) 0 1 (0.7)
Statin, %* 212 (65.2) 1149 (67.9) 130 (56.3) 1016 (69.2) 177 (66.5) 77 (56.2)
 Medications, final visit
Total, no. (SD)◊ 2.94 (0.96) 2.61 (0.98) 2.51 (0.86) 2.94 (0.96) 2.89 (0.91) 2.82 (0.82)
Metformin, %* 211 (64.9) 1206 (71.3) 165 (71.4) 966 (65.8) 171 (64.3) 79 (57.7)
Sulfonylurea, %* 68 (20.9) 618 (36.5) 73 (31.6) 443 (30.2) 89 (33.5) 39 (28.5)
DPP-4 Inhibitor, %* 46 (14.2) 394 (23.3) 34 (14.7) 343 (23.4) 48 (18.1) 19 (13.4)
GLP-1 Agonist, %* 60 (18.5) 241 (14.2) 20 (8.7) 270 (18.4) 41 (15.4) 15 (11)
SGLT-2 Inhibitor, %* 31 (9.5) 86 (5.1) 5 (2.2) 100 (6.8) 17 (6.4) 1 (0.7)
Thiazolidinedione, % 32 (9.9) 102 (6) 10 (4.3) 98 (6.7) 20 (7.5) 7 (5.1)
Insulin, %*
Basal/Bolus 216 (66.5) 662 (39.1) 97 (42) 856 (58.3) 158 (59.4) 102 (74.5)
Basal Only 62 (19.1) 415 (24.5) 77 (33.3) 345 (23.5) 64 (24.1) 19 (13.9)
Prandial Only 6 (1.9) 14 (0.8) 2 (0.9) 15 (1) 4 (1.5) 3 (2.2)
U-500 2 (0.6) 7 (0.4) 0 8 (0.5) 0 0
Statin, % 276 (84.9) 1404 (83) 180 (77.9) 1205 (82.1) 225 (84.6) 110 (80.3)
Comorbid Conditions, %
Alcohol Use Disorder* 29 (8.9) 151 (8.9) 23 (10) 100 (6.8) 28 (10.5) 20 (14.6)
Substance Use Disorder* 76 (23.4) 340 (20.1) 55 (23.8) 263 (17.9) 72 (27.1) 30 (21.9)
Hypertension* 278 (85.5) 1523 (90) 193 (83.6) 1344 (91.6) 238 (89.5) 120 (87.6)
Heart Failure* 41 (12.6) 176 (10.4) 18 (7.8) 199 (13.6) 29 (10.9) 17 (12.4)
A1c at goal within second year* 26 (8) 1041 (61.5) 101 (43.7) 185 (12.6) 3 (1.1) 0
*: p < 0.05 (ANOVA), ◊: p < 0.05 (Kruskal-Wallis)
BMI = Body mass index, BP = Blood pressure, HDL = High density lipoproteins, LDL = Low density lipoproteins, DPP-4 = Dipeptidyl peptidase-4,




between 9-10%. Also as expected, a greater proportion of patients in the Very Uncontrolled 
group were prescribed basal/bolus insulin at the end of pharmacist follow-up and that the rates of 
usage of insulin increased in all groups from baseline to the end of pharmacist follow-up. 
 
Interestingly, patients in the ‘Large Early Decline’ group showed a similar average duration of 
pharmacist management as the ‘Very Uncontrolled Stable’ group; however, those in the ‘Large 
Early Decline’ group had on average three more visits with a pharmacy provider. The reason for 
this is uncertain and an area for further inquiry; however, it is possible that early, more frequent 
contact is helpful. 
 
Finally, there generally was an increase in utilization of most classes of medications for 
treatment of diabetes (except sulfonylureas) which would be consistent with intensifying 
diabetes treatment regimens. Additionally, there appeared to be a consistent increase in the 
utilization of statins from baseline to the end of the 2-year study period or post-pharmacist 
management period. 
 
The ‘Moderate Early Decline’, ‘Large Early Decline’, and the ‘High Gradually Decreasing’ 
glycemic control trajectory groups were defined as ‘Successful’ trajectories (n = 2248, 55%) 
based on a sustained decrease in HbA1c over time. Conversely, the remaining three groups were 





Baseline and study period characteristics for those trajectories classified as ‘Successful’ versus 
‘Unsuccessful’ are shown in Table 2. 
Table 2: Characteristics based on successful vs unsuccessful trajectory groups 
 
Unsuccessful 
Trajectory                 
(n = 1871)
Successful 
Trajectory                   
(n = 2248)
P-Value
Age, yrs (SD) 63.9 (10.2) 64.3 (9.8) 0.189
Male, % 1802 (96.3) 2179 (96.9) 0.2721
Race, % 0.3981
White 1419 (75.8) 1689 (75.1)
Black or African American 351 (18.8) 452 (20.1)
Other 101 (5.4) 107 (4.8)
BMI, kg/m2 (SD) 34 (6.6) 33.9 (6.7) 0.5958
Pharmacy Visits, no. (SD)◊ 11.4 (8.5) 10.1 (7.6)
Telephone Visit, %, (SD) 12.7 (25.4) 12.8 (26.2) 0.8663
Clinical Video Telehealth, % (SD) 1.4 (10.4) 1.1 (8.9) 0.402
Home Telehealth, %* 477 (25.5) 440 (19.6) <0.0001
Nutrition/Weight Mgmt, % 0.4136
0-1 Visits 1422 (76) 1721 (76.6)
2-5 Visits 311 (16.6) 345 (15.4)
6+ Visits 138 (7.4) 182 (8.1)
Pharmacy follow-up duration (SD)* <0.0001
< 6 Months 342 (18.3) 636 (28.3)
6-12 Months 517 (27.6) 579 (25.8)
≥ 12 Months 1012 (54.1) 1033 (46)
Baseline A1c, % (SD) 9.9 (1.4) 10 (1.8) 0.0002
Creatinine Clearance, %* 0.0394
≥ 60 ml/min 1517 (81.1) 1869 (83.1)
30-59 ml/min 214 (11.4) 259 (11.5)
< 30 ml/min 25 (1.3) 25 (1.1)
Unknown 115 (6.2) 95 (4.2)
BP, baseline, mmHg (SD) 134/77 (18/12) 134/77 (17/12) 0.267  / 0.3938
BP, final, mmHg (SD) 133/76 (19/13) 133/76 (18/12) 0.4081 / 0.2712
Lipid levels, mg/dl, baseline:
Total Cholesterol (SD) 160.7 (46.1) 174.1 (55.8) 0.1753
Triglycerides (SD)◊ 197.7 (173.7) 242.5 (264.9) 0.001
HDL (SD) 37 (10) 36.9 (9.7) 0.5502
LDL (SD) 93.7 (35.4) 94.7 (37.8) 0.3881
Lipid levels, mg/dl, final visit
Total Cholesterol (SD)* 160.7 (46.1) 154.4 (44.4) <0.0001
Triglycerides (SD)◊ 197.7 (173.7) 179.9 (137.1) 0.0006
HDL (SD) 36.8 (9.4) 36.7 (9.4) 0.8796
LDL (SD)◊ 88.3 (34.7) 84.8 (33.2) 0.0016








Trajectory                 
(n = 1871)
Successful 




Total, no. (SD)◊ 2.12 (0.97) 1.94 (1) <0.0001
Metformin, % 1003 (53.6) 1241 (55.2) 0.3055
Sulfonylurea, % 681 (36.4) 823 (36.6) 0.8878
DPP-4 Inhibitor, % 138 (7.4) 182 (8.1) 0.3898
GLP-1 Agonist, %* 30 (1.6) 19 (0.9) 0.0254
SGLT-2 Inhibitor, % 2 (0.1) 1 (0) 0.594
Thiazolidinedione, % 52 (2.8) 70 (3.1) 0.5282
Insulin, %* <0.0001
Basal/Bolus 805 (43) 773 (34.4)
Basal Only 390 (20.8) 449 (20)
Prandial Only 47 (2.5) 31 (1.4)
U-500 5 (0.3) 4 (0.2)
Statin, % 1270 (67.9) 1491 (66.3) 0.2913
Medications, final visit
Total, no. (SD)◊ 2.92 (0.95) 2.65 (0.97) <0.0001
Metformin, %* 1216 (65) 1582 (70.4) 0.0002
Sulfonylurea, %* 571 (30.5) 759 (33.8) 0.0266
DPP-4 Inhibitor, % 410 (21.9) 474 (21.1) 0.5193
GLP-1 Agonist, %* 326 (17.4) 321 (14.3) 0.0058
SGLT-2 Inhibitor, % 118 (6.3) 122 (5.4) 0.2301
Thiazolidinedione, % 125 (6.7) 144 (6.4) 0.7219
Insulin, %* <0.0001
Basal/Bolus 1116 (59.7) 975 (43.4)
Basal Only 428 (22.9) 554 (24.6)
Prandial Only 22 (1.2) 22 (1)
U-500 8 (0.4) 9 (0.4)
Statin, % 1540 (82.3) 1860 (82.7) 0.7166
Comorbid Conditions, %
Alcohol Use Disorder 148 (7.9) 203 (9) 0.1999
Substance Use Disorder 365 (19.5) 471 (21) 0.2514
Hypertension* 1702 (91) 1994 (88.7) 0.017
Heart Failure* 245 (13.1) 235 (10.5) 0.0085
A1c at goal within second year* 188 (10.1) 1168 (54.6) <0.0001
*: p < 0.05 (t-test), ◊: p < 0.05 (Wilcoxon Rank Sum)
BMI = Body mass index, BP = Blood pressure, HDL = High density lipoproteins, 
LDL = Low density lipoproteins, DPP-4 = Dipeptidyl peptidase-4,




Those in groups classified as ‘Successful’ more often had a shorter duration of pharmacist 
follow-up and were less often enrolled in the home telehealth program. The home telehealth 
program is a program where Veterans can transmit health monitoring data (e.g. blood glucose 
readings) to registered nurses at the medical center to be provided to their diabetes provider. 
Demographics, modality of care delivery, nutrition clinic utilization, renal function, baseline 
HbA1c, and measures of blood pressure and lipid control were similar between the two groups of 
trajectories. While statistically significant, there was not a clinically meaningful difference 
between ‘Successful’ and ‘Unsuccessful’ trajectories in measured co-morbidities. Additionally, 
those in ‘Successful’ trajectories were more often prescribed metformin and less often prescribed 
Glucagon-like peptide 1 (GLP-1) agonists and basal/bolus insulin regimens. As would be 
expected, a significantly greater proportion of patients in ‘Successful’ trajectory groups attained 
goal HbA1c within the second study year (defined as at least one HbA1c value ≤ 7% between 
12-24 months).  
 
While those classified as following a successful trajectory group, on average, tended to show 
greater HbA1c during most time intervals, as seen in Table 3, the main difference appears to be a 
much larger improvement during the first three months, possibly indicating this could be a 
critical time for setting the stage for success. Of note, if subjects had missing HbA1c 



















Interval (Months) Mean HbA1c Change (%) SD n Mean HbA1c Change (%) SD n
0 to 3 -0.91 1.45 1539 -2.09 1.94 1945
3 to 6 -0.2 1.22 1211 -0.38 1.04 1456
6 to 9 0.02 1.25 976 -0.15 0.98 1057
9 to 12 -0.08 1.33 876 -0.23 1 879
12 to 15 -0.16 1.18 831 -0.3 1.11 777
15 to 18 -0.18 1.29 784 -0.29 1.02 737
18 to 21 -0.14 1.39 735 -0.11 1.03 691





3.4 Predictors of Successful Trajectories 
 
Logistic regression was completed to identify potential predictors of patients in successful 
trajectory groups versus unsuccessful, shown in Table 4.  




Intercept - - - 0.0532
Age 1.009 1.002 1.016 0.0101
Duration of Pharmacy Follow-up (Ref: < 6 Months) < 0.0001
6-12 Months 0.568 0.473 0.683 < 0.0001
≥ 12 Months 0.532 0.448 0.63 < 0.0001
Home Telehealth 0.796 0.681 0.93 0.0041
Nutrition Clinic Follow-up (Ref: 0-1 visits) 0.0853
2-5 visits 0.989 0.828 1.181 0.8995
6+ visits 1.307 1.027 1.667 0.0303
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min) 0.0091
30-59 ml/min 0.884 0.715 1.094 0.2564
< 30 ml/min 0.733 0.409 1.312 0.2934
Unknown 0.626 0.468 0.834 0.0014
Test strips/day 0.936 0.884 0.991 0.0225
Insulin at Baseline (Ref: None) < 0.0001
Basal/Bolus 0.701 0.594 0.826 < 0.0001
Basal only 0.815 0.681 0.976 0.0261
Prandial only 0.439 0.269 0.707 0.0008
U-500 0.61 0.149 2.342 0.4672
Medical Center (Ref: 1) < 0.0001
2 0.558 0.338 0.915 0.0215
3 0.889 0.565 1.389 0.6063
4 1.057 0.678 1.635 0.8051
5 0.592 0.362 0.959 0.0342
6 0.88 0.54 1.425 0.6043
7 1.027 0.664 1.577 0.9026
8 0.903 0.57 1.423 0.6624
Hosmer and Lemeshow Goodness of Fit Test (p = 0.1389)







Age, gender, race, medical center, duration of CPS management, use of home telehealth, 
nutrition clinic utilization, level of renal function, number of test strips dispensed, total number 
of medication classes prescribed for diabetes at baseline, type of insulin prescribed at baseline, 
diagnosis of alcohol use disorder or substance use disorder during the study period, and the 
proportion of CPS visits conducted via telephone or clinical video telehealth were initially 
entered into the model as potential predictors (see Appendix C for the full model). In order to 
obtain greater parsimony, after backwards elimination with a significance level to stay in the 
model of 0.1, the predictors in Table 4 above remained in the final model. 
 
Older age, shorter duration of pharmacist management, no use of the home telehealth program, 
extent of follow-up with nutrition clinic services, lower average number of glucose test strips 
provided per day, not utilizing insulin at baseline were significant predictors of patients being 
classified into a successful trajectory group. While level of creatinine clearance appeared to be a 
significant predictor of success, though the meaning of this is unclear as this seems to have been 
driven by those classified as ‘Unknown’ due to missing data for one or more of baseline height, 
weight, or serum creatinine level. Additionally, the medical center where care was provided was 
significantly associated with success indicating potential practice or patient population 







3.5 Relationship to Hospital Admissions 
 
Hospital admissions to non-psychiatric acute care units (e.g. excluding units such as psychiatric, 
skilled nursing, or domiciliary) were measured for each patient within the two-year study 
period.33 Logistic regression was performed to determine potential predictors of either all-cause 
or diabetes-related hospital admission. Initial models included predictors of age, gender, race, co-
morbidities, renal function, baseline HbA1c, VA medical center, and assigned glycemic control 
trajectory group (for the full models, see Appendix C). In order to obtain greater parsimony, 
models were then evaluated via backwards elimination with a significance level to stay in the 






The predictors in Table 5 below remained in the final model for occurrence of all-cause hospital 
admission after backwards elimination of predictors. 
Table 5: Predictors of all-cause hospital admission 
 
 
As would be expected, more advanced age, diagnoses of heart failure, alcohol use disorder, or 
substance use disorder, greater renal dysfunction, and greater baseline HbA1c were all associated 
with a greater odds of all-cause hospital admission. However, once baseline HbA1c was 
accounted for, trajectory group membership did not seem to affect odds of all-cause admission in 
Lower Upper
Intercept - - - <0.0001
Age 1.016 1.008 1.025 0.0002
Heart Failure 2.672 2.178 3.277 <0.0001
Alcohol Use Disorder 2.069 1.622 2.635 <0.0001
Substance Use Disorder 1.625 1.358 1.941 <0.0001
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min) <0.0001
30-59 ml/min 1.469 1.169 1.842 0.0009
< 30 ml/min 2.738 1.511 4.991 0.0009
Unknown 0.757 0.519 1.081 0.1365
Baseline HbA1c 1.112 1.043 1.186 0.0012
Trajectory Group (Ref: Moderate Early Decline) 0.0276
Large Early Decline 0.645 0.418 0.989 0.0461
High Gradually Decreasing 1.219 0.891 1.662 0.2129
Uncontrolled Stable 0.984 0.83 1.116 0.8536
Early Decline/Subsequent Increase 1.241 0.911 1.679 0.1663
Very Uncontrolled Stable 1.131 0.72 1.755 0.5875
Medical Center (Ref: 1) 0.004
2 0.786 0.444 1.422 0.4169
3 1.071 0.646 1.832 0.7951
4 1.172 0.716 1.981 0.5402
5 1.123 0.658 1.969 0.6778
6 1.196 0.7 2.101 0.5213
7 0.821 0.506 1.379 0.439
8 0.805 0.478 1.395 0.426
Hosmer and Lemeshow Goodness of Fit Test (p = 0.6594)
Predicted vs. Observed Percent Concordant = 65.7%





a meaningful way except possibly a slightly lower odds of hospitalization in the ‘Large Early 
Decline’ group as compared to the ‘Moderate Early Decline’ group. 
  
However, as seen in Table 6 below, assigned trajectory group did seem to be associated with 
differences in risk of diabetes-related admission. 
Table 6: Predictors of diabetes-related hospital admission 
 
 
Diagnosis of alcohol use disorder, substance use disorder, and worse baseline renal function 
remained important predictors of diabetes related hospital admissions. However, as opposed to 
solely baseline HbA1c level (see Appendix C for the full model), the assigned trajectory group of 
HbA1c change over time appeared to be related to diabetes-related admissions with the ‘Large 
Early Decline’ group showing no increased odds as compared to the ‘Moderate Early Decline’ 
group. Whereas the ‘High Gradually Decreasing’, ‘Uncontrolled Stable’, ‘Early 
Lower Upper
Intercept - - - <0.0001
Alcohol Use Disorder 2.086 1.326 3.199 0.001
Substance Use Disorder 1.921 1.341 2.724 0.0003
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min) 0.0005
30-59 ml/min 1.978 1.27 2.991 0.0017
< 30 ml/min 4.421 1.487 10.611 0.0025
Unknown 0.926 0.385 1.891 0.8486
Trajectory Group (Ref: Moderate Early Decline) <0.0001
Large Early Decline 0.886 0.302 2.085 0.8014
High Gradually Decreasing 3.314 1.914 5.618 <0.0001
Uncontrolled Stable 1.797 1.191 2.74 0.0056
Early Decline/Subsequent Increase 3.628 2.049 6.261 <0.0001
Very Uncontrolled Stable 6.579 3.544 11.82 <0.0001
Hosmer and Lemeshow Goodness of Fit Test (p = 0.7231)
Predicted vs. Observed Percent Concordant = 63.9%
95% Confidence Limits




Decline/Subsequent Increase’, and ‘Very Uncontrolled Stable’ groups all suggested higher odds 
of diabetes-related admission compared to the ‘Moderate Early Decline’ cohort.  
Though these results regarding diabetes-related hospital admissions must be interpreted 
cautiously as they were exploratory in nature and as seen in Table 7 below, the absolute number 
of diabetes-related admissions was very small.  
Table 7: Frequency of hospital admissions 
 
  
Glycemic Trajectory Group, n (%) Any Acute Admission Any DM Admission
High Gradually Decreasing 106 (32.6) 23 (7.1)
Moderate Early Decline 421 (24.9) 39 (2.3)
Large Early Decline 58 (25.1) 5 (2.2)
Uncontrolled Stable 369 (25.1) 58 (4)
Early Decline/Subsequent Increase 80 (30.1) 21 (7.9)













Diabetes is an important public health problem and the use of clinical pharmacists in diabetes 
management has shown to improve attainment of goal HbA1c.1-2,21-26 In addition to the final 
HbA1c attained at a single time point, recent research has shown that the trajectory of how that 
HbA1c is attained over time is also likely important for outcomes such as mortality, 
microvascular complications, and even cognitive function.16-20  While likely helpful in the 
management of T2DM, clinical pharmacy specialists trained in diabetes management are likely a 
scarce resource as compared to the total number of patients with T2DM. Thus, it is important to 
either determine which subsets of patients are most likely to have clinical success with 
pharmacist management of diabetes and/or determine strategies to help patients move from less 
successful trajectories of glycemic control to more successful ones. Utilizing a large sample of 
over 4,000 Veterans from eight VA medical centers, this study provides the first known 
evaluation of the distinct trajectories of HbA1c change after initiation of CPS management of 
T2DM.  
 
In this study, patients were able to be successfully segmented into six distinct trajectories of 
change in HbA1c over time after initiation of CPS management of diabetes (Figure 2 and Figure 
3). These trajectories can be distinguished by the general range of starting HbA1c (e.g. 
moderately uncontrolled versus very uncontrolled), how glycemic control changes over time 
(e.g. increasing, unchanged, or decreasing), and how quickly HbA1c changes over time (e.g. 
early or gradual). A large majority of patients either fell into the ‘Moderate Early Decline’ group 
(41.1%) or the ‘Uncontrolled Stable’ group (35.6%). Interestingly, these glycemic control 




plateau and are reasonably parallel. While a much smaller portion of the sample, a similar pattern 
is seen in the ‘Large Early Decline’ (5.6%) group with a large decrease in HbA1c over the first 
six months with a subsequent plateau. Overall, on average, except for the ‘High Gradually 
Decreasing’ group (7.9%), the first six months of CPS management appear crucial towards 
success at reaching therapeutic goals. This is further supported by the mean change in HbA1c 
over each 3-month time interval seen in Table 3, with the largest difference between successful 
and unsuccessful trajectories being in the 0 to 3-month timeframe. These results align with the 
recent VA study by Ourth et al. which showed that on average for their study population the 
greatest HbA1c improvement occurred within the first three months of either pharmacist 
management or usual care prior to plateauing.26 As CPS resources are relatively scarce as 
compared to the total number of patients suffering from diabetes, these data suggest possibly 
targeting those resources aggressively towards the first three to six months of management to 
have maximal impact. These data also suggest that it may be beneficial to examine pharmacist 
panels to identify and re-evaluate patients that are no longer achieving clinical progress with CPS 
management, focusing resources, to accept new patients with very uncontrolled HbA1c. The 
reasons for this early initial progress and subsequent plateauing are uncertain. It may indicate 
possible importance to creating an effective start to the CPS/patient relationship.  
 
Additionally, if the availability of clinical pharmacy specialist support is limited, it may be wise 
to prioritize patients with the most extreme baseline HbA1c readings (e.g. ≥ 11%) first. Out of 
the three HbA1c trajectories with a baseline HbA1c in this range, approximately 80% of patients 





Additionally, as most patients tended to fall into the ‘Moderate Early Decline’ or ‘Uncontrolled 
Stable” groups with similar baseline HbA1c values, a next step for further investigation would be 
to identify interventions that can help patients achieve a glycemic control trajectory more similar 
to the ‘Moderate Early Decline’ group rather than the ‘Uncontrolled Stable’ group. 
 
Another difference between those counted as being part of successful trajectories versus 
unsuccessful is that those following successful trajectories, on average, tended to have a shorter 
total duration of pharmacy follow-up. This could be related to achieving more reduction in 
HbA1c in the early months of CPS management. Also, though mean baseline HbA1c values 
were clinically similar, those patients classified as following unsuccessful trajectories were 
prescribed basal/bolus insulin. Additionally, being enrolled in the home telehealth program and 
being prescribed a greater number of glucose test strips were also associated with less likelihood 
of following a successful trajectory. These could indicate something about these patients that 
could be making them more difficult to manage. While not measured in this study, it could 
possibly be related to things such as duration of diabetes. Conversely, having had a total of more 
than 6 visits with the VA’s nutrition or weight management clinics was associated with 
likelihood of following a successful trajectory. This could be possibly related to direct effects of 
working with VA dieticians or it could also be a marker for an overall greater patient 
commitment to improving their diabetes control. Finally, there appeared to be some difference in 
likelihood of following a successful trajectory based on the medical center where care was 





Lastly, there did not seem to be a substantial effect of glycemic control trajectory on all-cause 
hospitalization occurrence once baseline HbA1c was accounted for. However, as may be 
expected, there possibly could be an association between trajectory of glycemic control and 
lower odds of diabetes-related hospital admission with patients assigned to trajectory groups 
where a greater proportion of patients reached HbA1c targets (‘Large Early Decline’ and 
‘Moderate Early Decline’). However, as noted, these results should be interpreted with caution 
given the exploratory nature of this analysis and the low absolute numbers of diabetes-related 




As this was a retrospective analysis, not all patients had HbA1c measurements for each study 
time point, the number of HbA1c values available analysis at each 3-month interval is shown in 
Table 8.  
Table 8: Available HbA1c Values at Each Time Interval 
 













While group-based trajectory modeling can accommodate data missing at random, it cannot be 
ruled out that there are commonalities between patients who did not have an HbA1c measured 
every three months, such as practice patterns of individual providers.31 Also, the trajectory 
groups that were determined are best fit measurements to a clustering of individual trajectories. 
Thus, the average trajectory pattern does not mean that individual patients follow that trajectory 
exactly. Some patients were not completely naïve to pharmacist management of diabetes. 
However, a one-year ‘wash-out’ period between any prior pharmacist management hopefully 
ensured capturing new episodes of pharmacist diabetes care. Also, there are several limitations 
associated with the use of retrospective data. Firstly, HbA1c measurements were completed as 
part of routine clinical care, and thus do not always occur exactly at the study interval 
breakpoints. While the most appropriate HbA1c value for each study interval was selected, 
patients may have had more than nine HbA1c measurements in the two-year study period and 
these ‘extra’ measurements are not taken into consideration in this analysis. However, given 
mechanistically how HbA1c is determined, we would not expect additional readings measured in 
the same time-frame to differ substantially in most cases.  Additionally, the presence of 
comorbidities is reliant on proper coding of medical record problem lists, clinic visits, and 
admissions. Also, medication dispensing records do not necessarily mean the patient was 
actively using that medication at home. These data also do not provide an assessment of how 
trajectories of glycemic control with pharmacist management compares with trajectories 
achieved by usual care by solely primary care provider management. These data cannot be 
applied to patient cohorts with baseline HbA1c values < 8%, these patients were excluded from 
the study cohort as many patients may have individualized HbA1c targets between 7-8% and 




providers for other reasons such as prevention of hypoglycemia or for other conditions such as 
hypertension where diabetes is assessed as a comorbidity rather than the primary focus of 
pharmacist management.  Finally, these data are aggregated, so they do not give any insight into 
how practice patterns of any individual pharmacist provider results in a specific set of 
trajectories.  
 
Also, overall, patient characteristics seemed similar for those classified into successful trajectory 
groups versus unsuccessful groups. It is likely that there are other unmeasured factors that 
contribute to a patient’s trajectory of glycemic control, many of which are not able to be 
measured in a retrospective analysis. Some of these factors could include the quality of the 
patient/pharmacist relationship, the degree of trust between the patient and CPS, characteristics 
of social support networks, lifestyle behaviors (e.g. dietary choices and changes in physical 
activity), and socioeconomic factors.  As expected, those classified into following successful 
trajectories were more likely to have achieved reaching an HbA1c goal of ≤ 7%. However, with 
current recommendations to individualize treatment targets in some patients such as for those 
with a high degree of comorbidities or diabetes complications, more patients might have actually 
achieved their individualized HbA1c targets.13 
 
Finally, while this study was able to show that there are subgroups of patients who have more 
success with pharmacy management of diabetes that are more likely to achieve goal HbA1c and 
that certain glycemic trajectories could confer greater risk of diabetes-related hospital admission, 




effect of these distinct trajectories on ultimate outcomes such as mortality or progression of 
diabetes complications.  
 
Considerations for Future Research 
 
It is an interesting finding that the first three to six months of pharmacist management may be 
crucial to determining a patient’s longer-term success with this clinical service. Further study 
could elucidate reasons for this trend and potentially identify best practices that help more 
patients follow successful trajectories. There is also opportunity for conducting prospective 
investigations aimed at designing strategies to help patients move from less successful to more 
successful glycemic control trajectories. Also, it could be valuable to investigate how trajectories 
of diabetes control change after completion or cessation of pharmacist management of diabetes 
to determine if glycemic control tends to be maintained or if it degrades. It could also be 
compared how these trajectories of diabetes control with pharmacist diabetes management differ 
from trajectories of diabetes control of propensity matched controls managed solely by primary 
care providers. Additionally, considering the future of health informatics, there could someday 
be the possibility of utilizing data glycemic control trajectories in conjunction with real-time data 
from continuous glucose monitoring, potentially on wearable technology, from large populations 
to inform machine learning algorithms to power clinical decision support tools to inform patients 
and providers of a patient’s current and anticipated trajectory helping clinicians and patients 
work together to improve that long-term outlook. Further study could be conducted on the 
difference in odds of diabetes-related hospital admission.  Finally, it remains to be evaluated if 




diabetes results in differences in long-term ultimate outcomes including mortality, longer-term 
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Appendix A: Model Selection Procedure 
 
Table 8 illustrates the steps taken in order when developing the model used for determining the 
best fitting glycemic control trajectories for use in PROC TRAJ in SAS. First, the number of 
groups were increased successively by one with each additional group being added modeled with 
a quadratic equation except for one group modeled as a zero-order group as it was thought there 
would likely be a subset of patients with no significant HbA1c change.31 
 





Step # Groups Group Orders BIC 2*DBIC Comment
1 2 0, 2 -46583.96 -
2 3 0, 2, 2 -45015.19 3137.54
3 4 0, 2, 2, 2 -43963.37 2103.64
4 5 0, 2, 2, 2, 2 -43701.21 524.32
5 6 0, 2, 2, 2, 2, 2 -43434.13 534.16 Maximum 6 groups reached
6 6 0, 3, 2, 2, 2, 2 -43036.65 794.96
7 6 0, 4, 2, 2, 2, 2 -42943.86 185.58
8 6 0, 5, 2, 2, 2, 2 -42977.56 -67.4 Return to order = 4 for group 2
9 6 0, 4, 3, 2, 2, 2 -42597.99 691.74 Step 7 = Null model
10 6 0, 4, 4, 2, 2, 2 -42550.46 95.06
11 6 0, 4, 5, 2, 2, 2 -42516.29 68.34
12 6 0, 4, 5, 3, 2, 2 -42334.62 363.34
13 6 0, 4, 5, 4, 2, 2 -42388.68 -108.12 Return to order = 3 for group 4
14 6 0, 4, 5, 3, 3, 2 -42512.69 -356.14 Group 1 drops out of model
15 6 2, 4, 5, 3, 3, 2 -42229 211.24 Trial order = 2 for group 1; Step 12 = Null model
16 6 2, 4, 5, 3, 4, 2 -42406.34 -354.68 Return to order = 3 for group 5
17 6 2, 4, 5, 3, 3, 3 -42455.62 -453.24 Return to order = 2 for group 6




The following table provides the parameter estimates defining the modeled trajectories of each 
group along with estimated proportions of group membership: 





T for H0: 
Parameter=0
Prob > |T|
1 Intercept 11.38067 0.11751 96.85 < 0.0001
Linear -0.15149 0.01834 -8.262 < 0.0001
Quadratic 0.00214 0.00066 3.236 0.0012
Group Membership (%) 7.90151 0.81855 9.653 < 0.0001
2 Intercept 9.22345 0.03166 291.324 < 0.0001
Linear -0.74999 0.02357 -31.816 < 0.0001
Quadratic 0.09634 0.0043 22.416 < 0.0001
Cubic -0.00497 0.00028 -17.829 < 0.0001
Quartic 0.00009 0.00001 15.19 < 0.0001
Group Membership (%) 39.98532 1.48293 26.964 < 0.0001
3 Intercept 13.41118 0.10319 129.963 < 0.0001
Linear 3.20694 0.10409 -30.811 < 0.0001
Quadratic 0.60532 0.03122 19.392 < 0.0001
Cubic -0.05159 0.00359 -14.381 < 0.0001
Quartic 0.00202 0.00017 11.726 < 0.0001
Quintic -0.00003 0 -10.108 < 0.0001
Group Membership (%) 5.73527 0.45764 12.532 < 0.0001
4 Intercept 9.41683 0.03957 237.982 < 0.0001
Linear -0.25646 0.0133 -19.282 < 0.0001
Quadratic 0.02028 0.00137 14.808 < 0.0001
Cubic -0.00048 0.00004 -12.628 < 0.0001
Group Membership (%) 35.87022 1.3047 27.493 < 0.0001
5 Intercept 10.28422 0.08753 117.489 < 0.0001
Linear -0.4484 0.0458 -9.79 < 0.0001
Quadratic 0.05171 0.00499 10.372 < 0.0001
Cubic -0.00135 0.00013 -10.241 < 0.0001
Group Membership (%) 7.16628 0.71797 9.981 < 0.0001
6 Intercept 12.15828 0.09593 126.747 < 0.0001
Linear -0.01282 0.02011 -0.637 0.5238
Quadratic 0.00091 0.00089 1.026 0.3051
Group Membership (%) 3.34139 0.31502 10.607 < 0.0001
s 1.07433 0.00516 208.153 < 0.0001
BIC = -42257.18 (N=25369), BIC = -42229 (N=4119), AIC = -42130.99, L = 42099.99
Maximum Liklihood Estimates




Appendix B: Trajectory Model Diagnostics 
 
Based on Nagin (2005), three assessments of fit of the data to the modeled glycemic control 
trajectory groups were assessed.33 These included an assessment of the mean posterior 
probabilities of assignment to each group where mean posterior probabilities > 0.7 indicate 
acceptable fit to the data, the odds of correct classification to the assigned trajectory group with 
values > 5 indicating acceptable fit to the data, and ratio of estimated group probabilities to the 
proportion of the sample assigned to each group which should be near one for each group.33 
 
Mean Posterior Group Probabilities 
 





         Mean Group Posterior Probability
1 2 3 4 5 6
1 0.80615 0.00175 0.01503 0.07946 0.07852 0.01808
2 0.00018 0.86679 0.01221 0.11962 0.00118 0.00001
3 0.01503 0.05856 0.86654 0.04893 0.00929 0.00166
4 0.02452 0.11316 0.00636 0.83061 0.0252 0.00015
5 0.071 0.00065 0.00437 0.06997 0.83901 0.015








Odds of Correct Classification  
 







Table 12: Odds of correct classification 
 
 
Ratio of Estimated Group Probabilities to the Proportion Assigned to Each Group 
 
Table 13: Ratio of estimated group probabilities to proportion assigned to each group 
 
 
Reasonableness Check for Glycemic Trajectory Group Assignments 
 
A random sample of 50 patients was drawn from each trajectory group via PROC 
SURVEYSELECT in SAS using simple random sampling. Those patient’s HbA1c values versus 
time were plotted to aid in confidence that the average trajectory paths that were determined are 
reasonable estimations of actual patient trajectories in the sample. Results of this random 
sampling for each trajectory group are displayed below in Figures 4 through 9. 

























Figure 4: High Gradually Decreasing Example Trajectories 
 














Figure 5: Moderate Early Decline Example Trajectories 
 














Figure 6: Large Early Decline Example Trajectories 
 














Figure 7: Uncontrolled Stable Example Trajectories 
 














Figure 8: Early Decline / Subsequent Increase Example Trajectories 
 














Figure 9: Very Uncontrolled Stable Example Trajectories 
  













Appendix C: Full Regression Models 
 
Predictors of Successful Trajectories 
 
The following table illustrates the full model of all predictors initially entered into the logistic 
regression model analysis prior to backwards selection of predictors. 
Table 14: Full model predictors of successful trajectories 
 
Lower Upper
Intercept - - - 0.0659
Age 1.011 1.003 1.018 0.0039
Duration of Pharmacy Follow-up (Ref: < 6 Months) < 0.0001
6-12 Months 0.571 0.475 0.686 < 0.0001
≥ 12 Months 0.543 0.456 0.644 < 0.0001
Home Telehealth 0.806 0.689 0.944 0.0073
Nutrition Clinic Follow-up (Ref: 0-1 visits) 0.0969
2-5 visits 0.98 0.82 1.172 0.8253
6+ visits 1.296 1.016 1.657 0.0374
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min) 0.0092
30-59 ml/min 0.868 0.7 1.078 0.1197
< 30 ml/min 0.742 0.411 1.339 0.3191
Unknown 0.627 0.469 0.837 0.0016
Test strips/day 0.935 0.883 0.99 0.0206
Insulin at Baseline (Ref: None) 0.0065
Basal/Bolus 0.769 0.631 0.937 0.0091
Basal only 0.86 0.708 1.045 0.1281
Prandial only 0.456 0.278 0.737 0.0015
U-500 0.61 0.149 2.341 0.4667
Medical Center (Ref: 1) < 0.0001
2 0.553 0.333 0.913 0.0212
3 0.882 0.559 1.383 0.5863
4 1.057 0.676 1.641 0.806
5 0.596 0.365 0.968 0.0373
6 0.896 0.55 1.452 0.657
7 1.078 0.686 1.682 0.7417
8 0.9 0.567 1.418 0.6506
Gender (Female) 0.878 0.617 1.249 0.4676
Race (Ref = White): 0.5475
Black 0.984 0.83 1.166 0.8488
Other 0.849 0.634 1.138 0.273
Ratio of Phone Appts 0.998 0.996 1.001 0.2878
Ratio of CVT Appts 1.001 0.994 1.008 0.7861
Total DM Meds (BL) 0.935 0.862 1.013 0.1016
Alcohol Use Disorder 1.142 0.902 1.449 0.2729
Substance Use Disorder 1.099 0.932 1.296 0.2634
Heart Failure 0.826 0.675 1.012 0.0649
CVT = Clinical Video Telehealth
Hosmer and Lemeshow Goodness of Fit Test (p = 0.2811)







Predictors of All-cause Hospital Admission 
 
The following table illustrates the full model of all predictors initially entered into the logistic 
regression model analysis prior to backwards selection of predictors. 
Table 15: Full model predictors of all-cause hospital admission 
Predictor (Any Admission) OR 
95% Confidence Limits 
p 
Lower Upper 
Intercept - - - <0.0001 
Age 1.016 1.007 1.025 0.0003 
Gender (Female) 0.943 0.609 1.42 0.7846 
Race (Ref: White)     0.3625 
Black of African American 1.019 0.838 1.235 0.8512 
Other 0.782 0.546 1.1 0.1677 
Heart Failure 2.674 2.18 3.28 <0.0001 
Alcohol Use Disorder 2.06 1.612 2.628 <0.0001 
Substance Use Disorder 1.628 1.36 1.945 <0.0001 
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min)    <0.0001 
30-59 ml/min 1.47 1.169 1.846 0.0009 
< 30 ml/min 2.831 1.558 5.177 0.0006 
Unknown 0.761 0.522 1.087 0.1441 
Baseline HbA1c 1.111 1.042 1.185 0.0013 
Trajectory Group (Ref: Moderate Early Decline)    0.0294 
Large Early Decline 0.65 0.42 0.996 0.0499 
High Gradually Decreasing 1.224 0.893 1.67 0.2055 
Uncontrolled Stable 0.988 0.833 1.17 0.8866 
Early Decline/Subsequent Increase 1.242 0.911 1.682 0.1647 
Very Uncontrolled Stable 1.131 0.72 1.758 0.5872 
Medical Center (Ref: 1)     0.0032 
2 0.779 0.439 1.409 0.399 
3 1.083 0.653 1.853 0.7643 
4 1.176 0.718 1.993 0.5316 
5 1.128 0.661 1.979 0.6656 
6 1.191 0.697 2.093 0.531 
7 0.807 0.479 1.399 0.4296 
8 0.807 0.479 1.399 0.4318 
Hosmer and Lemeshow Goodness of Fit Test (p = 0.4351)   






Predictors of Diabetes-related Hospital Admission 
 
The following table illustrates the full model of all predictors initially entered into the logistic 
regression model analysis prior to backwards selection of predictors. 
Table 16: Full model predictors of diabetes-related hospital admission 
 
Lower Upper
Intercept - - - <0.0001
Age 1.011 0.993 1.031 0.2318
Gender (Female) 1.296 0.531 2.7 0.5257
Race (Ref: White) 0.5727
Black of African American 1.111 0.74 1.644 0.6037
Other 0.706 0.288 1.478 0.3989
Heart Failure 1.085 0.667 1.698 0.7312
Alcohol Use Disorder 2.143 1.346 3.328 0.0009
Substance Use Disorder 1.893 1.311 2.706 0.0005
Creatinine Clearance, baseline (Ref: ≥ 60 ml/min) 0.0076
30-59 ml/min 1.79 1.103 2.836 0.0154
< 30 ml/min 4.199 1.361 10.638 0.0053
Unknown 1.296 0.531 2.7 0.7956
Baseline HbA1c 1.079 0.947 1.226 0.2486
Trajectory Group (Ref: Moderate Early Decline) <0.0001
Large Early Decline 0.659 0.198 1.861 0.4589
High Gradually Decreasing 2.931 1.542 5.479 0.0009
Uncontrolled Stable 1.803 1.191 2.759 0.0058
Early Decline/Subsequent Increase 3.549 1.956 6.288 <0.0001
Very Uncontrolled Stable 5.213 2.468 10.752 <0.0001
Medical Center (Ref: 1) 0.3386
2 0.806 0.215 3.853 0.7617
3 1.18 0.395 5.085 0.7927
4 0.893 0.301 3.84 0.8575
5 1.451 0.462 6.41 0.5657
6 0.466 0.111 2.335 0.3074
7 1.268 0.446 5.335 0.6982
8 0.965 0.31 4.239 0.9554
Hosmer and Lemeshow Goodness of Fit Test (p = 0.194)
Predicted vs. Observed Percent Concordant = 70.2%
Predictor (DM Admission) OR
95% Confidence Limits
p
